摘要
鼠双微体基因2(Mdm 2/Hdm 2)被认为是一种致癌基因,在包括乳腺癌在内的多种恶性肿瘤中异常表达。MDM2蛋白是肿瘤抑制蛋白P53的关键负调控因子,主要通过P53依赖途径抑制细胞周期停滞及细胞凋亡,继而发挥恶性作用。此外,MDM2还可以通过P53非依赖途径,如参与调控多条信号转导通路、通过其单核苷酸多态性影响个体对乳腺癌的易感性等,促进肿瘤的发生发展,而针对上述途径中涉及的各靶点的药物尚在不断研发中。本文旨在总结乳腺癌中MDM2发挥作用的机制及可能的治疗靶点,并将其转化为有临床应用价值的治疗手段,以促进乳腺癌患者的治疗,使患者更多获益。
Murine double minute 2(Mdm2/Hdm2)is considered an oncogene and is abnormally expressed in various malignancies including breast cancer.MDM2 protein is a critical negative regulator of tumor suppressor protein P53 and mainly inhibits cell cycle arrest and apoptosis through P53-dependent pathways,thereby playing a malignant role.In addition,MDM2 can also promote the development and progression of tumors through P53-independent pathways,such as participating in the regulation of multiple signal transduction pathways and affecting the susceptibility of individuals to breast cancer through its single nucleotide polymorphism,and drugs targeting each of the targets involved in the above pathways are constantly being developed.This article summarizes the mechanism of action and possible therapeutic targets of MDM2 in breast cancer and aims to transform it into a the-rapeutic method with clinical application value,so as to promote the treatment of breast cancer patients and bring more benefits to patients.
作者
黄婉莹
王书宝
李兆阳
杨向红
HUANG Wanying;WANG Shubao;LI Zhaoyang;YANG Xianghong(Department of Pathology,Shengjing Hospital,China Medical University,Shenyang 110004,China)
出处
《精准医学杂志》
2022年第6期471-475,480,共6页
Journal of Precision Medicine
基金
国家自然科学基金面上项目(81773108)。
